IRMD | Iradimed corp - Stock Value & PE Ratio Analysis

3

24

15

Good Growth

AI analysis rates IRMD with a higher value score of 4.
It is mainly due to stable revenue growth, along with stable operating cash flow.
Over the past 3 months, IRMD has maintained a consecutive value rating of 4.0, slightly higher than the rating of 3.5 over the past 3 years, indicating higher growth opportunities for enterprise value.
Compared to all stocks in the Health Care sector, IRMD has a higher value rating.

IRMD Value Reference Factors

The Value score is derived from various data and factor information, integrated through AI algorithms. The following factors are part of the evaluation used by AI value scores.

Update to 2025/02/21 (Weekly Update)

IRMD Financial Forecast

Unit : USD

Update to 2025/5/9 (Quarterly Update)

IRMD Earnings Table

Unit : USD

QTR	Non-GAAP EPS	EPS YoY	EPS Surprise %	Sales	Sales YoY	Sales Surprise %	NPM
Current	0.43	0%	10.3%	18.33M	11%	-3.2%	27.3%
2024Q1	0.42	16.7%	13.5%	17.93M	11.1%	1.6%	23.5%
2023Q4	0.36	20%	5.9%	17.6M	13.7%	2.7%	26%
2023Q3	0.39	21.9%	-2.5%	17.45M	17.4%	0.7%	30.7%
2023Q2	0.43	48.3%	19.4%	16.5M	23.1%	2.1%	25.9%

Update to 2025/5/10 (Quarterly Update)

IRMD Historical Value Score

You can use historical scores of 3 or above to observe potential performance and make investment decisions.

IRMD Value Strategy Backtest

The following backtest is based on specified rules since 2007. Price chart shows buy/sell time, cumulative returns, and backtesting statistics.

Entry

Exit

The Backtest Result of IRMD from 2014/07 till Now

246.65%
Cumulative Return: 12.20%
Annual Return: 37.03%
Volatility: 0.33
Sharpe Ratio

Statistics data for entering at or above a Value score of 4 and exiting at or below a Value score of 2 from July, 2014 to May, 2025. (Total Trades: 2)